Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Nahid Tabibzadeh, Lydie Cheval, Luciana Morla, Lucie Chevillard, Bruno Megarbane, Frank Bienaime, Emmanuelle Vidal-Petiot, Gilles Crambert
Lithium (Li+) salts are the most effective treatment of bipolar disorder (BD), affecting 1 to 4% of the population worldwide. However, this efficacy is counterbalanced by adverse long-term events, mostly renal effects. Lithium treatment discontinuation is usually not an option as it substantially increases suicidal risk. Understanding the sequence of events in the kidneys might thus improve therapeutic strategies while maintaining this treatment. Li+-induced nephrogenic diabetes insipidus (NDI) is the earliest and the most frequent side effect of chronic lithium use, leading to polyuria and polydipsia...
May 2022: FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology
#22
JOURNAL ARTICLE
Du Lei, Kun Qin, Wenbin Li, Walter H L Pinaya, Maxwell J Tallman, L Rodrigo Patino, Jeffrey R Strawn, David Fleck, Christina C Klein, Su Lui, Qiyong Gong, Caleb M Adler, Andrea Mechelli, John A Sweeney, Melissa P DelBello
BACKGROUND: Identification of treatment-specific predictors of drug therapies for bipolar disorder (BD) is important because only about half of individuals respond to any specific medication. However, medication response in pediatric BD is variable and not well predicted by clinical characteristics. METHODS: A total of 121 youth with early course BD (acute manic/mixed episode) were prospectively recruited and randomized to 6 weeks of double-blind treatment with quetiapine (n = 71) or lithium (n = 50)...
April 8, 2022: Psychological Medicine
#23
JOURNAL ARTICLE
Keming Gao, Marzieh Ayati, Mehmet Koyuturk, Joseph R Calabrese, Stephen J Ganocy, Nicholas M Kaye, Hillard M Lazarus, Eric Christian, David Kaplan
Purpose: To determine if enhanced flow cytometry ( CellPrint™ ) can identify intracellular proteins of lithium responsiveness in monocytes and CD4+ lymphocytes from patients with bipolar disorder. Methods: Eligible bipolar I or II patients were openly treated with lithium for 16-weeks. Baseline levels of Bcl2, BDNF, calmodulin, Fyn, phospho-Fyn/phospho-Yes, GSK3β, phospho-GSK3αβ, HMGB1, iNOS, IRS2, mTor, NLPR3, PGM1, PKA C-α, PPAR-γ, phospho-RelA, and TPH1 in monocytes and CD4+ lymphocytes of lithium responders and non-responders were measured with CellPrint™ ...
February 25, 2022: Psychopharmacology Bulletin
#24
JOURNAL ARTICLE
Andreas Göteson, Anniella Isgren, Timea Sparding, Jessica Holmén-Larsson, Joel Jakobsson, Erik Pålsson, Mikael Landén
We set out to identify novel protein associations with potential as clinically viable biomarkers for bipolar disorder. To this end, we used proximity extension assay to analyze 201 unique proteins in blood serum from two independent cohorts comprising patients with bipolar disorder and healthy controls (total n = 493). We identified 32 proteins significantly associated with bipolar disorder in both case-control cohorts after adjusting for relevant covariates. Twenty-two findings are novel to bipolar disorder, but 10 proteins have previously been associated with bipolar disorder: chitinase-3-like protein 1, C-C motif chemokine 3 (CCL3), CCL4, CCL20, CCL25, interleukin 10, growth/differentiation factor-15, matrilysin (MMP-7), pro-adrenomedullin, and TNF-R1...
February 8, 2022: Translational Psychiatry
#25
JOURNAL ARTICLE
Paul Beunon, Maxime Barat, Anthony Dohan, Lynda Cheddani, Lisa Males, Pedro Fernandez, Bruno Etain, Frank Bellivier, Emeline Marlinge, François Vrtovsnik, Emmanuelle Vidal-Petiot, Antoine Khalil, Jean-Philippe Haymann, Martin Flamant, Nahid Tabibzadeh
BACKGROUND: Lithium therapy during bipolar disorder is associated with an increased risk of chronic kidney disease (CKD) that is slowly progressive and undetectable at early stages. We aimed at identifying kidney image texture features as possible imaging biomarkers of decreased measured glomerular filtration rate (mGFR) using radiomics of T2-weighted magnetic resonance imaging (MRI). METHODS: One hundred and eight patients treated with lithium were evaluated including mGFR and kidney MRI, with T2-weighted sequence single-shot fast spin-echo...
May 2022: European Journal of Clinical Investigation
#26
RANDOMIZED CONTROLLED TRIAL
Wenbin Li, Du Lei, Maxwell J Tallman, Yuan Ai, Jeffrey A Welge, Thomas J Blom, David E Fleck, Christina C Klein, Luis R Patino, Jeffrey R Strawn, Qiyong Gong, Stephen M Strakowski, John A Sweeney, Caleb M Adler, Melissa P DelBello
OBJECTIVE: Disruptions in cognition are a clinically significant feature of bipolar disorder (BD). The effects of different treatments on these deficits and the brain systems that support them remain to be established. METHOD: A continuous performance test was administered to 55 healthy controls and 71 acutely ill youths with mixed/manic BD to assess vigilance and working memory during task-based functional magnetic resonance imaging studies. Patients, who were untreated for at least 7 days at baseline, and controls were scanned at pretreatment baseline and at weeks 1 and 6...
August 2022: Journal of the American Academy of Child and Adolescent Psychiatry
#27
JOURNAL ARTICLE
Claudia Pisanu, Giovanni Severino, Ilario De Toma, Mara Dierssen, Paolo Fusar-Poli, Massimo Gennarelli, Pietro Lio, Elisabetta Maffioletti, Eduard Maron, Divya Mehta, Alessandra Minelli, Marie-Claude Potier, Alessandro Serretti, David Stacey, Roos van Westrhenen, Laura Xicota, Bernhard T Baune, Alessio Squassina
Variation in the expression level and activity of genes involved in drug disposition and action in tissues of pharmacological importance have been increasingly investigated in patients treated with psychotropic drugs. Findings are promising, but reliable predictive biomarkers of response have yet to be identified. Here we conducted a PRISMA-compliant systematic search of PubMed, Scopus and PsycInfo up to 12 September 2020 for studies investigating RNA expression levels in cells or biofluids from patients with major depressive disorder, schizophrenia or bipolar disorder characterized for response to psychotropic drugs (antidepressants, antipsychotics or mood stabilizers) or adverse effects...
February 2022: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
#28
JOURNAL ARTICLE
Sara Sadat Aghabozorg Afjeh, Jamal Shams, Safar Hamednia, Behzad Boshehri, Asmaolhosna Amini, Amin Omrani, Mir Davood Omrani
Background: Lithium is a therapeutic option for the treatment of the acute phase of the bipolar disorder and long-term management of this disorder. However, it is estimated that 10 to 60% of patients do not properly response to this medication. Methods: To investigate the role of MARK2 gene in response to lithium, we genotyped the MARK2 rs10792421 polymorphism in Iranian bipolar patients using amplification Refractory Mutation System-PCR. Results: Results of this study showed a significant association of this polymorphism with response to lithium...
March 1, 2022: Iranian Biomedical Journal
#29
JOURNAL ARTICLE
Arthur M Butt, Andrea D Rivera
Bipolar disorder (BD) is a complex group of neuropsychiatric disorders, typically comprising both manic and depressive episodes. The underlying neuropathology of BD is not established, but a consistent feature is progressive thinning of cortical grey matter (GM) and white matter (WM) in specific pathways, due to loss of subpopulations of neurons and astrocytes, with accompanying disturbance of connectivity. Dysregulation of astrocyte homeostatic functions are implicated in BD, notably regulation of glutamate, calcium signalling, circadian rhythms and metabolism...
2021: Advances in Neurobiology
#30
JOURNAL ARTICLE
Jan Scott, Mohamed Lajnef, Romain Icick, Frank Bellivier, Cynthia Marie-Claire, Bruno Etain
Optimal classification of the response to lithium (Li) is crucial in genetic and biomarker research. This proof of concept study aims at exploring whether different approaches to phenotyping the response to Li may influence the likelihood of detecting associations between the response and genetic markers. We operationalized Li response phenotypes using the Retrospective Assessment of Response to Lithium Scale (i.e., the Alda scale) in a sample of 164 cases with bipolar disorder (BD). Three phenotypes were defined using the established approaches, whilst two phenotypes were generated by machine learning algorithms...
October 23, 2021: Pharmaceuticals
#31
JOURNAL ARTICLE
Eva H I Claeys, Tim Mantingh, Manuel Morrens, Nefize Yalin, Paul R A Stokes
OBJECTIVE: Abnormalities in spontaneous brain activity, measured with resting-state functional magnetic resonance imaging (rs-fMRI), may be key biomarkers for bipolar disorders. This systematic review compares rs-fMRI findings in people experiencing a bipolar depressive or (hypo)manic episode to bipolar euthymia and/or healthy participants. METHODS: Medline, Web of Science and Embase were searched up until April 2021. Studies without control group, or including minors, neurological co-morbidities or mixed episodes, were excluded...
March 8, 2022: Progress in Neuro-psychopharmacology & Biological Psychiatry
#32
JOURNAL ARTICLE
Johan Fernström, Lars Ohlsson, Marie Asp, Eva Lavant, Amanda Holck, Cécile Grudet, Åsa Westrin, Daniel Lindqvist
BACKGROUND: Plasma circulating cell-free mitochondrial DNA (ccf-mtDNA) is an immunogenic molecule and a novel biomarker of psychiatric disorders. Some previous studies reported increased levels of ccf-mtDNA in unmedicated depression and recent suicide attempters, while other studies found unchanged or decreased ccf-mtDNA levels in depression. Inconsistent findings across studies may be explained by small sample sizes and between-study variations in somatic and psychiatric co-morbidity or medication status...
2021: PloS One
#33
RANDOMIZED CONTROLLED TRIAL
Rahim Badrfam, Seyed-Ali Mostafavi, Ali Khaleghi, Shahin Akhondzadeh, Atefeh Zandifar, Malihe Farid, Nami Mohammadian Khonsari, Mohammad Reza Mohammadi
OBJECTIVE: Vitamin B6 has been linked to a variety of probable roles, including anti-inflammatory, homocysteine-lowering, serotonin-regulating, and dopamine-lowering. In this study, we investigated the possible effect of vitamin B6 on bipolar disorder in manic episode with psychotic feature in a placebo-controlled double-blind clinical trial in a psychiatric hospital. METHODS: This study was performed on 50 patients who were equally divided into two groups (each group included 25 patients) using 80 mg of vitamin B6 daily or placebo...
November 2021: Brain and Behavior
#34
JOURNAL ARTICLE
Sigrid Le Clerc, Laura Lombardi, Bernhard T Baune, Azmeraw T Amare, Klaus Oliver Schubert, Liping Hou, Scott R Clark, Sergi Papiol, Micah Cearns, Urs Heilbronner, Franziska Degenhardt, Fasil Tekola-Ayele, Yi-Hsiang Hsu, Tatyana Shekhtman, Mazda Adli, Nirmala Akula, Kazufumi Akiyama, Raffaella Ardau, Bárbara Arias, Jean-Michel Aubry, Lena Backlund, Abesh Kumar Bhattacharjee, Frank Bellivier, Antonio Benabarre, Susanne Bengesser, Joanna M Biernacka, Armin Birner, Clara Brichant-Petitjean, Pablo Cervantes, Hsi-Chung Chen, Caterina Chillotti, Sven Cichon, Cristiana Cruceanu, Piotr M Czerski, Nina Dalkner, Alexandre Dayer, Maria Del Zompo, J Raymond DePaulo, Bruno Étain, Stephane Jamain, Peter Falkai, Andreas J Forstner, Louise Frisen, Mark A Frye, Janice M Fullerton, Sébastien Gard, Julie S Garnham, Fernando S Goes, Maria Grigoroiu-Serbanescu, Paul Grof, Ryota Hashimoto, Joanna Hauser, Stefan Herms, Per Hoffmann, Esther Jiménez, Jean-Pierre Kahn, Layla Kassem, Po-Hsiu Kuo, Tadafumi Kato, John R Kelsoe, Sarah Kittel-Schneider, Ewa Ferensztajn-Rochowiak, Barbara König, Ichiro Kusumi, Gonzalo Laje, Mikael Landén, Catharina Lavebratt, Susan G Leckband, Alfonso Tortorella, Mirko Manchia, Lina Martinsson, Michael J McCarthy, Susan L McElroy, Francesc Colom, Vincent Millischer, Marina Mitjans, Francis M Mondimore, Palmiero Monteleone, Caroline M Nievergelt, Markus M Nöthen, Tomas Novák, Claire O'Donovan, Norio Ozaki, Urban Ösby, Andrea Pfennig, James B Potash, Andreas Reif, Eva Reininghaus, Guy A Rouleau, Janusz K Rybakowski, Martin Schalling, Peter R Schofield, Barbara W Schweizer, Giovanni Severino, Paul D Shilling, Katzutaka Shimoda, Christian Simhandl, Claire M Slaney, Claudia Pisanu, Alessio Squassina, Thomas Stamm, Pavla Stopkova, Mario Maj, Gustavo Turecki, Eduard Vieta, Julia Veeh, Stephanie H Witt, Adam Wright, Peter P Zandi, Philip B Mitchell, Michael Bauer, Martin Alda, Marcella Rietschel, Francis J McMahon, Thomas G Schulze, Jean-Louis Spadoni, Wahid Boukouaci, Jean-Romain Richard, Philippe Le Corvoisier, Caroline Barrau, Jean-François Zagury, Marion Leboyer, Ryad Tamouza
Bipolar affective disorder (BD) is a severe psychiatric illness, for which lithium (Li) is the gold standard for acute and maintenance therapies. The therapeutic response to Li in BD is heterogeneous and reliable biomarkers allowing patients stratification are still needed. A GWAS performed by the International Consortium on Lithium Genetics (ConLiGen) has recently identified genetic markers associated with treatment responses to Li in the human leukocyte antigens (HLA) region. To better understand the molecular mechanisms underlying this association, we have genetically imputed the classical alleles of the HLA region in the European patients of the ConLiGen cohort...
September 8, 2021: Scientific Reports
#35
EDITORIAL
Balwinder Singh, Francisco Romo-Nava, Alfredo B Cuellar-Barboza
No abstract text is available yet for this article.
2021: Frontiers in Psychiatry
#36
JOURNAL ARTICLE
Theun de Groot, Rosalinda Doty, Lars Damen, Ruben Baumgarten, Steffi Bressers, Joline Kraak, Peter M T Deen, Ron Korstanje
Chronic lithium treatment for bipolar disease causes mainly side effects in the kidney. A subset of lithium users develops nephrogenic diabetes insipidus (NDI), a urinary concentrating disorder, and chronic kidney disease (CKD). Age, lithium dose, and duration of treatment are important risk factors, whereas genetic background might also play an important role. To investigate the role of genetics, female mice of 29 different inbred strains were treated for 1 year with control or lithium chow and urine, blood, and kidneys were analyzed...
September 1, 2021: Physiological Genomics
#37
REVIEW
C Marie-Claire, B Etain, F Bellivier
Lithium (Li) remains the first line long-term treatment of bipolar disorders notwithstanding a high inter-individual variability of response. Significant research effort has been undertaken to understand the molecular mechanisms underlying Li cellular and clinical effects in order to identify predictive biomarkers of response. Li response has been shown to be partly heritable, however mechanisms that do not rely on DNA variants could also be involved. In recent years, modulation of epigenetic marks in relation with the level of Li response has appeared increasingly plausible...
September 14, 2021: Neuroscience Letters
#38
JOURNAL ARTICLE
Sairah Sharif, Bohan Chen, Pamela Brewster, Tian Chen, Lance Dworkin, Rujun Gong
Background: Burgeoning pre-clinical evidence suggests that therapeutic targeting of glycogen synthase kinase 3β (GSK3β), a convergence point of multiple cellular protective signaling pathways, confers a beneficial effect on acute kidney injury (AKI) in experimental models. However, it remains unknown if GSK3β inhibition likewise mitigates AKI in humans. Cardiac surgery associated acute kidney injury (CSA-AKI) poses a significant challenge for clinicians and currently the only treatment available is general supportive measures...
2021: Frontiers in Medicine
#39
JOURNAL ARTICLE
Shiqian Han, Huiwen Zhang, Mengni Yi, Xiaoqing Liu, Gustavo H B Maegawa, Yunding Zou, Qijun Wang, Dianqing Wu, Zhijia Ye
Background: Niemann-Pick disease type C1 (NP-C1) is a rare, autosomal-recessive neurodegenerative disorder with no United States Food and Drug Administration (FDA)-approved drug. Lithium has been shown to have considerable neuroprotective effects for neurological disorders such as bipolar disorder, Alzheimer's disease and stroke and has been tested in many clinical trials. However, the pharmacological effect of lithium on NP-C1 neurodegenerative processes has not been investigated. The aim of this study was to provide an initial evaluation of the safety and feasibility of lithium carbonate in patients with NP-C1...
2021: Frontiers in Pharmacology
#40
JOURNAL ARTICLE
Keita Idemoto, Tomihisa Niitsu, Tatsuki Hata, Tamaki Ishima, Sumiko Yoshida, Kotaro Hattori, Tadasu Horai, Ikuo Otsuka, Hidenaga Yamamori, Shigenobu Toda, Yosuke Kameno, Kiyomitsu Ota, Yasunori Oda, Atsushi Kimura, Tasuku Hashimoto, Norio Mori, Mitsuru Kikuchi, Yoshio Minabe, Ryota Hashimoto, Akitoyo Hishimoto, Kazuyuki Nakagome, Kenji Hashimoto, Masaomi Iyo
Glial cell line-derived neurotrophic factor (GDNF) plays an important role in the pathophysiology of neuropsychiatric disorders. We examined serum GDNF levels in bipolar disorder (BD) patients and major depressive disorder (MDD) patients and their association with response to lithium therapy. We used a multicenter (six sites), exploratory, cross-sectional case-control design and recruited 448 subjects: 143 BD patients, 116 MDD patients, and 158 healthy controls (HCs). We evaluated the patients' clinical severity using the Clinical Global Impression (CGI), and responses to lithium therapy using the Alda scale...
April 27, 2021: Psychiatry Research
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
